Intercept Pharmaceuticals (ICPT) PT Lowered to $16 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- L3Harris CEO steps down amid conduct review, shares drop
Intercept Pharma (ICPT) Tops Q1 EPS by 22c
May 6, 2021 7:57 AM EDTIntercept Pharma (NASDAQ: ICPT) reported Q1 EPS of ($1.22), $0.22 better than the analyst estimate of ($1.44). Revenue for the quarter came in at $81.66 million versus the consensus estimate of $81.2 million.
Our global commercial strategy and our continued progress in educating specialists including gastroenterologists have produced another quarter of double-digit sales growth for Ocaliva, said Jerry Durso, President and Chief Executive Officer of Intercept. As we continue our dialogue with FDA, which is reaching its conclusion regarding updates to the Ocaliva U.S. Prescribing Information, we expect that the final label will restrict Ocaliva in patients with... More
